Showing 781-790 of 9358 results for "".
- Amazon Launches $5-a-Month Subscription Service for Generic Drugshttps://practicaldermatology.com/news/amazon-launches-5-a-month-subscription-service-for-generic-drugs-1/2461518/In its latest move into the healthcare and pharmacy business, Amazon announced the launch of RxPass, a new benefit for Prime members that offers patients access to commonly prescribed generic medications that treat more than 80 health conditions. With RxPass, which is part of Amazon Pharmacy, Prim…
- Sun Pharma Launches New AH-ha! It’s Acne Hormones Campaignhttps://practicaldermatology.com/news/sun-pharma-launches-new-ah-ha-its-acne-hormones-campaign/2461509/Sun Pharmaceutical Industries, Inc, is launching "AH-ha! It's Acne Hormones," an awareness campaign featuring Sandra Lee, MD (AKA TLC's "Dr. Pimple Popper"). The campaign is designed to spotlight hormones as a major underlying cause of acne, regardless of age, gender, or ethnicity, and dispel mis…
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative…
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D array of volumetric thermal zones that delive…
- Zubin Meshginpoosh Named President and COO at Sentéhttps://practicaldermatology.com/news/zubin-meshginpoosh-named-president-and-coo-at-sente/2461463/Zubin Meshginpoosh is now the President and Chief Operational Officer of Senté. "Zubin has an incredible track record for enabling teams to achieve success in high growth and fast-changing environments," says Faheem Hasnain, Chairman of the Board at Senté, in a news release. "Zubin joined Senté in…
- UCB’s Bimekizumab Performs Well in PsA Studieshttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-psa-studies/2461460/Two new studies highlight the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and/or tumor necrosis factor inhibitor inadequate responders (TNFi-IR). The 24-week results from the Phase 3 BE OPTIMAL study and 16-week results from…
- Cosmetic Surgery Forum 2022 Kicks Off in Nashvillehttps://practicaldermatology.com/news/cosmetic-surgery-forum-2022-kicks-off-in-nashville/2461451/Now in its 14th year, the 2022 Cosmetic Surgery Forum is once again taking Nashville by storm with new faculty members, a new roundtable, and exciting new topics along with the frank discussions, candor, and live demos that attendees have come to expect. “CSF 2022 is our best year ever! We are …
- Almirall Appoints Mercedes Diz as VP, Corporate Strategyhttps://practicaldermatology.com/news/almirall-appoints-mercedes-diz-as-vp-corporate-strategy/2461449/Almirall named Mercedes Diz as its VP Corporate Strategy. Diz will also join Almirall's Management Board of Directors, effective December 1. Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Strategy, leading key strategic processes and projects for…
- Galderma Sponsors 21st Annual SCOPE Miami Beach 2022 Art Showhttps://practicaldermatology.com/news/galderma-sponsors-21st-annual-scope-miami-beach-2022-art-show/2461447/Galderma is the exclusive aesthetic injectables sponsor of the 21st annual SCOPE Miami Beach 2022 art show. Galderma will be highlighting its aesthetics portfolio – Restylane, Dysport (abobotulinumtoxinA) and Sculptra – and hosting a variety of activations for visitors beginning November 29th thro…
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology breakth…